The Impact of No-Call Rate in NIPT
An infographic that highlights the clinical importance of no-call rate in NIPT (non-invasive prenatal testing).
Articles and resources
SOFTWARE AS A SERVICE LICENSE AGREEMENT (EVOYA™ PLATFORM)
SOFTWARE AS A SERVICE LICENSE AGREEMENT (EVOYA™ PLATFORM) To view the file click the link here:
https://rh.perkinelmer.com/wp-content/uploads/2023/07/EVOYATM-Platform-SAAS-TERMS-AND-CONDITIONS_2023SEPTEMBER11.pdf
Addressing evolving laboratory needs through innovative workflows
Revvity's Symposium presentation from ESHG 2023 (European Society of Human Genetics). A compilation of talks from forward-thinking laboratory leaders, highlighting their innovative methods and services.
Webinar: 1st trimester pre-eclampsia screening – From invention to implementation
In this webinar, the father of FMF pre-eclampsia prediction models, Professor Kypros Nicolaides provides his insights to current developments and future prospects in this field. As one remarkable milestone in the journey from invention to implementation of pre-eclampsia screening is the first recommendation in public health to offer preterm pre-eclampsia screening to all women in Ontario, Canada.
Welcome to Revvity
Welcome to Revvity, where we are expanding the boundaries of human potential through science. Together with our customers and partners, we embrace the impossible to bring this purpose to life.
The impact of newborn screening – an interview with Heidi Wallis
Heidi Wallis - the Executive Director of the Association of Creatine Deficiencies, discusses the importance of newborn screening, and the potential impact it can have. Heidi discusses her own experiences as a parent of a child with GAMT.
Revvity Tests Included in UK’s Updated NICE Diagnostic Guidance for Pre-Eclampsia DG-49
Two Revvity CE marked tests are recommended in latest version of NICE guidance “PLGF-based testing to help diagnose suspected preterm pre-eclampsia” for UK healthcare providers
Designing a quantitative PCR assay for fetal RhD genotyping from maternal plasma derived cell free fetal DNA (cffDNA)
M.Sc. Suvi Parviainen and Ph.D. Ville Veikkolainen. Poster presented at the ESHG conference 2022.
Consequences of imprecision in fetal fraction estimation on performance of cell-free DNA screening for Down syndrome
Persson F. and Cuckle H.S., Prenat Diagn. 2022
World View Newborn Screening Congress
We are very excited to announce the World View Newborn Screening Summit 2022 from 28-30th June in conjunction with International Neonatal Screening Day. There will be discussion around the latest advances in screening, but also hearing from those projects initiating new screening services. This event will have over 20 presentations from participants from 11 different countries. The sessions will be live streamed during the event and will be available ‘On-Demand’ after the event for those who register. Registration for the World View Newborn Screening Summit is free, and there will be opportunity to submit questions during the event to the speakers.
Products may not be licensed in accordance with the laws in all countries, such as the United States, Canada. Please check with your local representative for availability.
Revvity does not endorse or make recommendations with respect to research, medication, or treatments. All information presented is for informational purposes only and is not intended as medical advice. For country specific recommendations please consult your local health care professionals.
